Common Stock, par value $0.0001 per share
- Symbol
- SE
- Exchange
- NYSEAMER
- Classification
- COMMON
Current Report · Items 8.01, 9.01 · 8-K
Serina Therapeutics, Inc.
SERNYSE_AMERICANEQUITYCurrent
Other Events
Item 8.01 Other Items On January 28, 2026, the Company issued a press release announcing that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SER-252, an investigational therapy for advanced Parkinson’s disease.…
Company context
We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ Platform™ (“POZ”) drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that may provide an improved efficacy and safety profile of the resulting polymeric drug conjugate. Our business is largely focused on the development of a wholly-owned pipeline of POZ-enabled drug candidates for central nervous system (“CNS”) indications, including Parkinson’s disease. Our lead product candidate, SER-252 (POZ-apomorphine), is a POZ conjugate of the dopamine agonist apomorphine being developed for the treatment of advanced Parkinson’s disease. In January 2026, we received clearance of our Investigational New Drug application from the U.S. Food and Drug Administration for SER-252. In February 2026, we enrolled and dosed our first patient in our Phase 1b single-ascending dose (“SAD”) clinical trial for SER-252. For additional information about our business, operations, and financial results, see the documents listed under “Where You Can Find More Information.”
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by Sio Capital Management, LLC regarding Serina Therapeutics, Inc.Nov 3, 2026
- Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 9, 2026
- Other EventsSep 9, 2026
- EFFECT filingAug 31, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesAug 27, 2026
Registered securities in this filing
Serina Therapeutics, Inc. · 8-K · Filed 2026-01-28
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Items
On January 28, 2026, the Company issued a press release announcing that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SER-252, an investigational therapy for advanced Parkinson’s disease. The IND clearance allows Serina to proceed with regulatory and site-level activities to support initiation of a planned Phase 1b registrational clinical study evaluating SER-252 in patients with advanced Parkinson’s disease. A copy of the press release is filed as Exhibit 99.1 to this Current Report and is incorporated herein by reference.